Skip to content
Bored Studies
RecruitingPhase 1

Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

Incyte Corporation · NCT07049575

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 12–75 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 1
Target enrollment
24
US sites recruiting
16
Study start
November 3, 2025
Record last updated
October 9, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this study is to evaluate the maximal use of ruxolitinib cream in adult and adolescent participants with hidradenitis suppurativa.

Being studied: Ruxolitinib Cream

Conditions: Hidradenitis Suppurativa

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Diagnosis of HS for at least 6 months before screening visit.
  • Diagnosis of HS (Hurley Stage I, II, III) with a total abscess and inflammatory nodule count of at least 4 and affecting at least 3 distinct anatomical areas at screening and Day 1 visits.
  • Total estimated treatment BSA > 20% at screening and baseline.
  • Agreement to not use topical or systemic antibiotics for treatment of HS during the Maximal Use Treatment Period.
  • Willingness to avoid pregnancy or fathering children based on the criteria defined in the protocol.
  • Further inclusion criteria apply.

Exclusion Criteria

  • Current or history of skin condition(s) other than HS that might confound the evaluation of HS; clinically uncontrolled cardiovascular disease; thrombosis; certain cancers; certain infections; severe anemia, thrombocytopenia, or neutropenia; other medical conditions at the discretion of the investigator.
  • Laboratory values outside of the protocol-defined ranges.
  • Further exclusion criteria apply.

Recruiting US locations

Study contacts (from the official record)

  • Incyte Corporation Call Center (US) · 1.855.463.3463 · medinfo@incyte.com
  • Incyte Corporation Call Center (ex-US) · +800 00027423 · eumedinfo@incyte.com
All dermatology studies in Arizona →
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult… (NCT07049575) | Bored Studies